Profile data is unavailable for this security.
About the company
Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.
- Revenue in INR (TTM)22.83bn
- Net income in INR4.71bn
- Incorporated2011
- Employees1.82k
- LocationGlenmark Life Sciences LtdGlenmark HouseB. D. Sawant Marg, Andheri (East)MUMBAI 400099IndiaIND
- Phone+91 2 268297979
- Websitehttps://www.glenmarklifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Orchid Pharma Ltd | 8.12bn | 1.25bn | 51.72bn | 838.00 | 35.78 | -- | 32.54 | 6.37 | 28.50 | 26.84 | 175.33 | -- | -- | -- | -- | 9,691,729.00 | -- | -1.07 | -- | -1.96 | 41.49 | 45.87 | 15.63 | -3.52 | -- | 4.34 | -- | -- | 19.00 | -0.6456 | 187.87 | -- | 68.72 | -- |
Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 65.91bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 68.85bn | 407.00 | -- | -- | -- | 64.54 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
Marksans Pharma Ltd | 21.03bn | 3.17bn | 70.74bn | 1.40k | 22.15 | -- | 18.27 | 3.36 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
F D C Ltd | 19.16bn | 2.90bn | 72.51bn | 6.37k | 25.27 | -- | 22.06 | 3.78 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
Strides Pharma Science Ltd | 39.53bn | -1.52bn | 76.59bn | 2.85k | -- | -- | 129.48 | 1.94 | -16.88 | -10.96 | 436.72 | -- | -- | -- | -- | 13,871,790.00 | -- | -0.9448 | -- | -1.59 | 58.90 | 49.75 | -4.37 | -2.19 | -- | 0.9061 | -- | -- | 20.13 | 5.33 | 51.93 | -- | -25.10 | -5.59 |
Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 77.39bn | 1.41k | 36.18 | -- | 32.15 | 6.62 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
Wockhardt Ltd | 27.76bn | -5.01bn | 81.44bn | 2.74k | -- | -- | -- | 2.93 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
Neuland Laboratories Ltd. | 15.81bn | 3.17bn | 91.69bn | 1.57k | 28.92 | -- | 24.53 | 5.80 | 247.14 | 247.14 | 1,232.07 | -- | -- | -- | -- | 10,048,590.00 | -- | 5.69 | -- | 7.95 | 51.76 | 43.56 | 20.06 | 8.07 | -- | 28.54 | -- | 8.27 | 25.25 | 17.62 | 156.21 | 68.43 | -13.12 | -- |
Granules India Ltd | 45.26bn | 3.95bn | 95.03bn | 3.65k | 24.03 | -- | 15.89 | 2.10 | 16.32 | 16.32 | 186.88 | -- | -- | -- | -- | 12,400,240.00 | -- | 11.15 | -- | 16.55 | 51.94 | 49.35 | 8.73 | 12.39 | -- | 6.53 | -- | 10.08 | 19.84 | 21.67 | 25.16 | 31.26 | -1.66 | 8.45 |
Caplin Point Laboratories Ltd | 16.30bn | 4.38bn | 96.63bn | 777.00 | 22.20 | -- | 19.74 | 5.93 | 57.33 | 57.33 | 213.53 | -- | -- | -- | -- | 20,980,180.00 | -- | 21.04 | -- | 24.25 | 56.48 | 52.84 | 27.08 | 25.02 | -- | 845.56 | -- | 9.37 | 15.54 | 22.13 | 25.49 | 21.05 | 31.87 | 17.61 |
Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 102.11bn | 1.82k | 21.71 | 4.38 | 19.47 | 4.47 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
Jubilant Pharmova Ltd | 66.22bn | 378.60m | 107.55bn | 1.03k | 280.29 | -- | 18.35 | 1.62 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
Eris Lifesciences Ltd | 18.61bn | 3.86bn | 115.38bn | 3.55k | 29.90 | -- | 21.26 | 6.20 | 28.36 | 28.36 | 136.57 | -- | -- | -- | -- | 5,245,254.00 | -- | 17.62 | -- | 20.12 | 82.02 | 80.57 | 20.36 | 27.34 | -- | 7.94 | -- | -- | 25.10 | 14.52 | -5.90 | 5.38 | 101.87 | -- |
Astrazeneca Pharma India Ltd | 11.97bn | 1.39bn | 128.32bn | 947.00 | 92.12 | -- | 82.93 | 10.72 | 55.72 | 55.72 | 478.78 | -- | -- | -- | -- | 12,640,230.00 | -- | 10.51 | -- | 18.10 | 59.93 | 58.05 | 11.64 | 9.11 | -- | 132.84 | -- | 11.82 | 24.50 | 11.89 | 61.19 | 30.82 | 6.29 | -- |
Holder | Shares | % Held |
---|---|---|
Polar Capital LLPas of 31 Jan 2024 | 1.02m | 0.83% |
Union Asset Management Co. Pvt Ltd.as of 31 Mar 2024 | 973.44k | 0.79% |
NTAsset (Thailand) Co., Ltd.as of 31 Dec 2021 | 950.65k | 0.78% |
Jupiter Asset Management Ltd.as of 31 Jan 2024 | 583.22k | 0.48% |
HSBC Global Asset Management (Hong Kong) Ltd.as of 30 Jun 2023 | 541.99k | 0.44% |
Mellon Investments Corp.as of 04 Apr 2024 | 213.17k | 0.17% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 143.39k | 0.12% |
Fiduciary Management, Inc.as of 29 Feb 2024 | 125.00k | 0.10% |
TIAA-CREF Investment Management LLCas of 29 Feb 2024 | 94.03k | 0.08% |
Norges Bank Investment Managementas of 31 Dec 2023 | 88.79k | 0.07% |